Insights

Why is the Telix (ASX:TLX) share price jumping 8% today?

The biopharmaceutical company is having a good week.
The post Why is the Telix (ASX:TLX) share price jumping 8% today? appeared first on The Motley Fool Australia. –

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is continuing its good run this week amid a company announcement on its study to treat bladder cancer.

The biopharmaceutical company has informed investors it has delivered its first dose to a patient in a Phase 1 study investigating non-muscle-invasive bladder cancer (NMIBC).

At the time of writing, the Telix share price is at $8.04, an 8.65% jump on yesterday’s close. Earlier, it reached a high of $8.10.

A first step in cancer study

Telix updated the market on its targeted alpha therapy candidate TLX250-CDx for bladder cancer. The therapy is designed to target a receptor overexpressed in many solid tumours, including urologic malignancies.

The current study is being conducted in Nantes with Telix’s French-based partner Atonco. It will trial the therapy on 6 patients over 12 months.

NMIBC accounts for around 75-85% of new bladder cancer diagnoses. Bladder cancer is the sixth most common form of cancer for men and the tenth most common cancer worldwide

Telix is hoping its product will deliver “high amounts of energy” to cancer tissue whilst also decreasing the risk of damage to healthy cells, making radiation treatment more effective.

In July 2020, the US Food and Drug Administration (FDA) granted Breakthrough Therapy (BT) designation for TLX250-CDx in the fight against kidney cancer.

Telix’s chief medical officer Dr Colin Hayward said the company was looking to extend TLX250-CDx’s development for numerous cancer types where there is “unmet medical need”.

Cancer treatment is not Telix’s only project. Just yesterday, the Telix share price gained more than 7% as it announced that the US Food and Drug Agency had approved its prostate cancer imaging product Illuccix.

In other company news this morning, Telix also announced it would cease a number of its securities due to “expiry of option or other convertible security without exercise or conversion”.

In all, the company ceased more than 1 million securities, including various option and rights shares.

Telix share price snapshot

The Telix share price has shot up an impressive 101% over the last 12 months.

Telix has a market capitalisation of more than $2.2 billion with just over 285 million shares issued.

The post Why is the Telix (ASX:TLX) share price jumping 8% today? appeared first on The Motley Fool Australia.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of August 16th 2021

More reading

Why Australian Clinical Labs, Magellan, Sandfire, and Telix shares are rising

What’s with the Telix (ASX:TLX) share price yo-yo today?

What’s the outlook for ASX biotech shares in 2022?

Why Grange, Iluka, Perpetual, and Telix shares are rising today

Here’s why the Telix (ASX:TLX) share price is falling today

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!